The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts

Robyn Marie Scherber, Holly Lynn Geyer, Amylou C. Dueck, Heidi E. Kosiorek, Guido Finazzi, Riccardo Cavazzina, Arianna Masciulli, Marco Scarano, Alessandro M. Vannucchi, Ruben A. Mesa, Tiziano Barbui

Resultado de la investigación: Articlerevisión exhaustiva

13 Citas (Scopus)

Resumen

Current guidelines suggest that polycythemia vera (PV) patients maintain a strict hematocrit less than 45%. However, to date, little is known about the relationship between HCT control and PV- related symptom burden. In this study, PV patient data was analyzed from the CYTO PV trial (n = 224) and the MPN-SAF study cohort (n = 645). No significant differences in symptom burden were seen at the 6 and 12 month follow-up when evaluating prospective hematocrit control in the CYTO PV cohort. Patients in the MPN-SAF cohort with a worst item score of greater than 5/10 on the Myeloproliferative Neoplasm Symptom Total Symptom Score had a significantly lower mean hematocrit (p =.0376). These findings suggest a relationship between traditional aggressive therapy for PV and increased symptom burden with prolonged therapy. Thus, symptom burden should be considered when contemplating the choice of therapy in the second-line setting for PV.

Idioma originalEnglish (US)
Páginas (desde-hasta)1481-1487
Número de páginas7
PublicaciónLeukemia and Lymphoma
Volumen58
N.º6
DOI
EstadoPublished - jun. 3 2017
Publicado de forma externa

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Huella

Profundice en los temas de investigación de 'The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts'. En conjunto forman una huella única.

Citar esto